Form SC 13G/A GENOCEA BIOSCIENCES, Filed by: CVF, LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Biosciences (GNCA) Tops Q4 EPS by 3c
February 11, 2016 8:41 AM ESTGenocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $221 thousand versus the consensus estimate of $40 thousand.
For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.
... More